Anti-Kininogen 1 antibody
Specifications
| Product Cat#: | AB-06-2600 |
| Product type: | Primary antibody |
| Antigen: | Kininogen 1 |
| Immunogen: | Recombinant protein within human Kininogen 1 aa 500-644 |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:500-1:2000); Immunohistochemistry(1:50-1:200) |
| Reactivity: | Human, Mouse |
| Clonality (clone number): | Monoclonal (JE43-72) |
| Form: | Liquid |
| Buffer: | TBS (pH7.4), 1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| Alternative names: | Alpha-2-Thiol Proteinase Inhibitor antibody |
| BDK antibody | |
| BK antibody | |
| Bradykinin antibody | |
| Bradykinin included antibody | |
| Fitzgerald Factor antibody | |
| FLAUJEAC FACTOR antibody | |
| High Molecular Weight Kininogen antibody | |
| HMWK antibody | |
| Ile-Ser-Bradykinin antibody | |
| Kallidin I antibody | |
| Kallidin II antibody | |
| KNG antibody | |
| KNG1 antibody | |
| KNG1_HUMAN antibody | |
| Low Molecular Weight Growth-Promoting Factor antibody | |
| WILLIAMS FACTOR antibody | |
| Williams-Fitzgerald-Flaujeac Factor antibody |
Target information
1 Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Provider
Erpantech Laboratory
